Bioavailability: Difference between revisions
Jump to navigation
Jump to search
imported>Howard C. Berkowitz (New page: '''Bioavailability''' is the degree to which a drug or other substance becomes available to the target tissue after administration. <ref name=Cancerweb>{{citation | title = Bioavailabilit...) |
imported>Howard C. Berkowitz No edit summary |
||
Line 1: | Line 1: | ||
{{subpages}} | |||
'''Bioavailability''' is the degree to which a drug or other substance becomes available to the target tissue after administration. <ref name=Cancerweb>{{citation | '''Bioavailability''' is the degree to which a drug or other substance becomes available to the target tissue after administration. <ref name=Cancerweb>{{citation | ||
| title = Bioavailability | | title = Bioavailability | ||
Line 9: | Line 10: | ||
| contribution = Subcapter D, Drugs for Human Use, Part 320: Bioavailability and Bioequivalence requirements | | contribution = Subcapter D, Drugs for Human Use, Part 320: Bioavailability and Bioequivalence requirements | ||
| url = http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=320.24 }}</ref> | | url = http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=320.24 }}</ref> | ||
==References== | |||
{{reflist}} |
Revision as of 13:24, 3 December 2008
Bioavailability is the degree to which a drug or other substance becomes available to the target tissue after administration. [1] For bioavailability to be verified, there must be a chemical, biological, immunologic, or other test that verifies the concentration of the drug, or its active derivative, in the body fluids of the recipient.
Bioequivalence covers the case where the initial distribution of different drug preparations may vary, but the duration and form of the active principle is delivered identically. [2]
References
- ↑ Bioavailability
- ↑ , Subcapter D, Drugs for Human Use, Part 320: Bioavailability and Bioequivalence requirements, US Code of Federal Regulations, April 1, 2008, 21CFR320.24